이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
BioNTech 관리
관리 기준 확인 4/4
BioNTech's CEO는 Ugur Sahin, Jan2008 에 임명되었습니다 의 임기는 16.42 년입니다. 총 연간 보상은 € 3.06M, 22.9% 로 구성됩니다. 22.9% 급여 및 77.1% 보너스(회사 주식 및 옵션 포함). 는 $ 3.56B 가치에 해당하는 회사 주식의 17.11% 직접 소유합니다. 3.56B. 경영진과 이사회의 평균 재임 기간은 각각 5.4 년과 4.2 년입니다.
주요 정보
Ugur Sahin
최고 경영자
€3.1m
총 보상
| CEO 급여 비율 | 22.9% |
| CEO 임기 | 16.4yrs |
| CEO 소유권 | 17.1% |
| 경영진 평균 재임 기간 | 5.4yrs |
| 이사회 평균 재임 기간 | 4.2yrs |
최근 관리 업데이트
Recent updates
Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet
Jun 16
BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical
Jun 13Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year
May 11Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report
May 08BioNTech Earnings Preview: I Will Stay On The Sidelines
May 03BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09CDC advisory panel recommends COVID vaccines for children be included in federal program
Oct 19Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?
Oct 18Hong Kong approves BioNTech COVID vaccine for infants
Oct 12EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids
Oct 03CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | €113m |
| Dec 31 2023 | €3m | €700k | €930m |
| Sep 30 2023 | n/a | n/a | €3b |
| Jun 30 2023 | n/a | n/a | €4b |
| Mar 31 2023 | n/a | n/a | €6b |
| Dec 31 2022 | €6m | €360k | €9b |
| Sep 30 2022 | n/a | n/a | €10b |
| Jun 30 2022 | n/a | n/a | €12b |
| Mar 31 2022 | n/a | n/a | €13b |
| Dec 31 2021 | €12m | €360k | €10b |
| Sep 30 2021 | n/a | n/a | €7b |
| Jun 30 2021 | n/a | n/a | €4b |
| Mar 31 2021 | n/a | n/a | €1b |
| Dec 31 2020 | €17m | €360k | €15m |
| Sep 30 2020 | n/a | n/a | -€410m |
| Jun 30 2020 | n/a | n/a | -€230m |
| Mar 31 2020 | n/a | n/a | -€192m |
| Dec 31 2019 | €7m | €311k | -€179m |
| Sep 30 2019 | n/a | n/a | -€122m |
| Jun 30 2019 | n/a | n/a | -€116m |
| Mar 31 2019 | n/a | n/a | -€77m |
| Dec 31 2018 | €653k | €210k | -€48m |
보상 대 시장: Ugur 의 총 보상 ($USD 3.28M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 13.50M ).
보상과 수익: Ugur 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Ugur Sahin (59 yo)
16.4yrs
테뉴어
€3,056,000
보상
Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Co-Founder | 16.4yrs | €3.06m | 17.11% € 3.3b | |
| Co-Founder | 6.4yrs | €814.00k | 0.38% € 73.4m | |
| CFO & Member of Management Board | 2.9yrs | €1.32m | 0.00067% € 129.9k | |
| MD, COO & Member of Management Board | 10.4yrs | €821.00k | 0.31% € 60.7m | |
| Chief Strategy Officer | 4.4yrs | €1.41m | 0.0061% € 1.2m | |
| Chief Business Officer | 12.4yrs | €133.00k | 0.34% € 65.5m | |
| Chief Legal Officer & Member of the Management Board | less than a year | €848.00k | 데이터 없음 | |
| Senior Vice President of Corporate Development & Strategy | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior VP & External Consultant for RNA Protein Replacement Therapies | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Operations | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Immunotherapy & Preclinical Research | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Global R&D Digital | no data | 데이터 없음 | 데이터 없음 |
5.4yrs
평균 재임 기간
57yo
평균 연령
경험이 풍부한 관리: BNTX 의 관리팀은 노련하고 경험 (평균 재직 기간 5.4 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Supervisory Board Member | 2yrs | €90.00k | 0.00017% € 33.0k | |
| Independent Deputy Chairman Supervisory Board | 6.4yrs | €114.00k | 데이터 없음 | |
| Independent Supervisory Board Member | 16.4yrs | €80.00k | 데이터 없음 | |
| Independent Supervisory Board Chairman | 16.4yrs | €226.00k | 0.14% € 26.7m | |
| Member of Supervisory Board | 1.1yrs | €46.00k | 데이터 없음 | |
| Supervisory Board Member | 2yrs | €105.00k | 0.00010% € 19.4k |
4.2yrs
평균 재임 기간
58.5yo
평균 연령
경험이 풍부한 이사회: BNTX 의 이사회는 경험(평균 재직 기간 4.2 년)으로 간주됩니다.